Kolodney

Michael S. Kolodney, MD, PhD

Chairman, Department of Dermatology

Contact

Send an Email
Phone
855-988-2273
Fax
304-285-7381
Room
G126, HSC North, Floor Ground
Address
PO Box 9158
School of Medicine
Department of Dermatology
Health Sciences Center, Box 9158
Morgantown, WV 26506-9158
View Clinical Profile
Additions & Corrections?

Positions

Chairman, Department of Dermatology

Organization:
School of Medicine
Department:
Dermatology
Classification:
Faculty

Member

Organization:
WVU Cancer Institute
Classification:
Faculty

Education

  • BS, Massachussetts Institute of Technology, Cambridge, MA, 1986
  • MD, Washington University, St. Louis, MO, 1995
  • PhD, Washington University, St. Louis, MO, 1995

Publications

   Research Papers - Peer Reviewed , 2010-Present

  1. Lacy FA, Coman GC, Holliday AC, Kolodney MS. (2018) Assessment of Smartphone Application for Teaching Intuitive Visual Diagnosis of Melanoma. JAMA Dermatol. 154(6):730–731.

  2. Coman, G. C., Holliday, A. C., Mazloom, S. E., Chavan, R. N., & Kolodney, M. S. (2017). A randomized, split‐face, controlled, double‐blind, single‐centre clinical study: transient addition of a topical corticosteroid to a topical retinoid in patients with acne to reduce initial irritation. British Journal of Dermatology, 177(2), 567-569

  3. Holliday, A. C., Mazloom, S. E., Coman, G. C., Kolodney, M. S., Chavan, R. N., & Grider, D. J. (2017). Benign glandular schwannoma with ancient change. The American Journal of dermatopathology, 39(4), 300-303

  4. Eikenberg, Mazloom, S. E., Holliday, A. C., Coman, G. C., Chavan, R. N., Kolodney, M. S., & Grider, D. J. (2016). Type I Cutaneous Meningioma (Rudimentary Meningocele) With Intradural Attachment to the Phylum Terminale. The American Journal of Dermatopathology, 38(12), 927-929.

  5. J. D., Grider, D. J., & Kolodney, M.S. (2015). Use of Clamping to Enhance Intralesional Bleomycin Therapy for Nodular Basal Cell Carcinoma. , (1), 7-8

  6. Jayaraman, SS, Rayhan, DJ, Hazany, S & Kolodney, MS (2014) Mutational Landscape of Basal Cell Carcinomas by Whole-Exome Sequencing. J. Invest Derm. Journal of Investigative Dermatology; 2014 134(1):213-20

  7. Thuangtong R, Bentow J, Knopp K, Mahmood NA, David NE, and Kolodney MS (2010) Tissue-selective effects of injected deoxycholate.Dermatologic Surgery 36(6):899-908

  8. Nobe K, Hiroko Y, Nobe H, Kolodney MS, Paul RJ, and Honda K (2010) Rho A and the Rho kinase pathway regulate fibroblast contraction enhanced contraction in constitutive active Rho A fibroblast cells. Biochem. Biophys. Res. Commun. 399(2):292-9

   Research Papers - Non Peer Reviewed 2010-Present

  1. Kolodney, MS.(2010)“Infliximab Safe, Effective for Reducing Severity of HS” Prac. Rev. in Derm. 24-09

  2. Kolodney, MS.(2010)“The High Cost of Biologics for Psoriasis” Prac. Rev. in Derm. 24-09

  3. Kolodney, MS.(2010)“Do Children With Psoriasis Have Similar Comorbidities as Adults?” Prac. Rev. in Derm. 24-09

  4. Kolodney, MS.(2010)“Cosmeceutical Regimen Equally Effective, Better Tolerated Than Tretinoin” Prac. Rev. in Derm. 24-10

  5. Kolodney, MS.(2010)“BTX Is Only Helpful for Certain Types of Migraine” Prac. Rev. in Derm. 24-10

  6. Kolodney, MS.(2010)“Does Tx Choice Determine Onychomycosis Recurrence After Mycological Cure?”Prac. Rev. in Derm. 24-10

  7. Kolodney, MS.(2010)“Is Ciclosporine Superior to Prednisolone for Adult Eczema?” Prac. Rev. in Derm. 24-10

  8. Kolodney, MS.(2010)“Ustekinumab vs Etanercept for Psoriasis” Prac. Rev. in Derm. 24-10

  9. Kolodney, MS.(2010)“Long-Term Use of Voriconazole Is Associated With Melanoma” Prac. Rev. in Derm. 24-10

  10. Kolodney, MS.(2010)“Are Anti-TNF Biologics Effective for Dissecting Cellulitis?” Prac. Rev. in Derm. 24-11

  11. Kolodney, MS.(2010)“Dermatomyositis Really Is Associated With Malignancy” Prac. Rev. in Derm. 25-01

  12. Kolodney, MS.(2010)“Can Switching to Sirolimus Reduce Skin Cancer Risks in Renal Transplant Patients?”Prac. Rev. in Derm. 25-05

  13. Kolodney, MS.(2010)“Varicella Infection Before Age 10 Years May Reduce Atopic Dermatitis” Prac. Rev. in Derm. 25-08

  14. Kolodney, MS.(2010)“Does Platelet Activation Play a Role in Psoriasis?” Prac. Rev. in Derm. 25‑01

  15. Kolodney, MS.(2010)“Consider Intralesional Chemotherapy for Classic KS” Prac. Rev. in Derm. 25-04

  16. Kolodney, MS.(2010)“Is Isotretinoin Associated With IBD?” Prac. Rev. in Derm. 25-04

Full list of publications can be viewed in the link below

Publications Link

Awards

Honors and Awards

Outstanding leadership Award, "In Recognition of Exceptional leadership and Devoted Service to the Harbor UCLA Division of Dermatology" 2012 

Victor D Newcomer Award, "Presented at the 55th Annual Meeting of Pacific Dermatologic Association"  2003 

Victor Newcomer Teaching Award, "For Outstanding Teaching of UCLA Dermatology Residents" 2001, 2002, 2003

James Henry Yalem Prize in Dermatology, "For Outstanding Work in Dermatology by a Senior Medical Student"  1995 

Spencer T. and Ann W. Olin Fellowship, "In Recognition of Superior Achievement in Biomedical Research"   1993 

James Barret Brown Prize, "For Advancement of Knowledge in the Field of Plastic and Reconstructive Surgery"  1988

 

Additional Info

Professional & Scholarly Associations

Association of Professors of Dermatology          9/2006

Society for Investigative Dermatology                7/2000

American Academy of Dermatology                   7/2000

Editorial Services

Editor: Practical Reviews in Dermatology          1/2007-05/2011

Editorial Board: Procedural Dermatology           10/2015

About Michael Kolodney

Personal interests:  Skiing; biking; poker

Michael S. Kolodney, M.D.-PhD, FAAD is Chairman of the Department of Dermatology at the West Virginia University (WVU) School of Medicine in Morgantown, West Virginia.  In the School of Medicine at WVU, he holds an appointment as Professor of Dermatology. 

Dr. Kolodney earned a Bachelor of Science (B.S.) degree in physics from MIT.  He earned his MD-PhD degrees from Washington University School of Medicine in St. Louis,.  Dr. Kolodney completed a combined residency in Dermatology and Internal Medicine at UCLA. He is board-certified in Dermatology by the American Board of Dermatology.  He no longer maintains his board certification in Internal Medicine.

Dr. Kolodney was previously chief of Dermatology at Harbor-UCLA medical center and established a new Dermatology Residency Program there. He then became Chief of Dermatology at the Va Tech Carilion School of medicine and established a new Dermatology Residency Program there as well. He has previously served as the editor for Practical Reviews in dermatology. Dr. Kolodney has co-authored numerous peer-reviewed papers and has received honors and awards recognizing excellence in teaching and research. Of note, he developed a first in class drug to treat double chins that that has been FDA approved and is currently marketed by Allergan.  His research is currently focused on  translational approaches to imaging, genomics and therapy of skin diseases.

Grants and Research

Polynoma Inc. MAVIS trial - Seviprotimut-L Vaccine for Melanoma Recurrence   $65,000       1/2015

Amgen Inc. $45,000 A Prospective Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance      5/2014

Amgen Inc. $600,000  AMAGINE-2 Trial (Anti IL-17 for Psoriasis) Role: P.l. for Carilion site      3/2013

Kythera Inc. Sponsored research agreement with to develop therapeutics targeting adipose tissue $1,700,000 Role: Principal Investigator      9/05-7/12

Kemia Inc. $10,000 Use of KC706 for the Treatment of Pemphigus Vulgaris Role: P.l. for Harbor-UCLA Site       1/01/2008

Dermatology Foundation $20,000 Program Development Grant Role: Principal Investigator       7/1/2006-6/30/2007

UCLA Center for Biological Radio-protectors $50,000 Mediators of radiation dermatitis Role: Principal Investigator      7/1/2006-6/30/2007

NIH 1-R41-HG003959-01  Fiber Optics Based Bioluminescence Imaging  $107,000  Role: Principal Investigator  10/1/2005 - 10/1/2006

Genentech Raptiva  RESPONSE Study  $25,000  Role: Principal Investigator for Harbor site   9/1/2005-9/1/2007

LaBiomed Seed Grant 12076-01 MEK as a therapeutic target for B-raf mutated  Melanomas  $25,000  Role: Principal Investigator   1/1/2005-12/31/2006

Harbor-UCLA GCRC  Effect of Topical Corticosteroids on Epidermal  Adhesion Strength in Pemphigus Vulgaris  $20,000 Role: Principal Investigator  7/1/2004-6/30/2005

Research Awards Program Prevention of Melanoma Metastasis through inhibition of RhoC isoprenylation $100,000 Role: Principal Investigator  7/1/2003-6/30/2005

Stein-Oppenheimer  Research Award Effects of Braf inhibition on melanoma metastasis formation $20,000 Role: Principal Investigator   7/1/2003-6/30/2004

Melanoma Research foundation Inhibition of rhoC Prenylation by Statins $60,000  Role: Principal Investigator   7/1/2002-6/30/2004

Dermatology Foundation Career Development Award  Mechanism of Spongiotic Change $110,000 Role: Principal Investigator   1/1/200-12/31/2002

Los Angeles Dermatology Foundation, Mechanism of Spongiotic Change  $15,000  Role: Principal Investigator    1/1/2000-12/31/2001

Dermatology Foundation  Mechanism of Spongiotic Change  $10,000  Role: Principal Investigator    1/1/2000-12/31/2001

Additional Info

Intellectual property and Patent Royalties

   Patents

Matrix cells for cultivation of muscle tissue in collagen gel and a method for measurement of isometric force parameters, with an apparatus for carrying out the method. (1996 Pat.# 19500498 in Germany) T. Eschenhagen, E.L. Elson, M.S. Kolodney, T. Wakatsuki

 

Patient Care Information

Medical Specialties

  • Dermatology

Board Certifications

  • Dermatology, American Board of Dermatology

Special Training

  • Fellowship, Research Fellow in Dermatology
    UCLA School of Medicine, Los Angeles, CA, 2000
  • Residency, Resident in Dermatology and Internal Medicine
    UCLA School of Medicine, Los Angeles, CA, 1999
  • Other Speciality Training, Intern in Internal Medicine
    Brown University / Rhode Island Hospital, Providence, RI, 1996